Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | APP | P05067 | 1/20 | 1.00 |
| ▸ | GBA1 | P04062 | 4/20 | 0.50 |
| ▸ | MGAM | O43451 | 6/20 | 0.33 |
| ▸ | FUCA1 | P04066 | 5/20 | 0.33 |
| ▸ | GLA | P06280 | 2/20 | 0.33 |
| ▸ | GANC | Q8TET4 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2512806 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL12711208 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL187278 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL1055883 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL21388397 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL13058696 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL12735687 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| SCHEMBL2511997 | 1.00 | — | — | |
| Inositol SCHEMBL2422938 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 | |
| Scyllitol SCHEMBL187397 | 1.00 | LMNA (1.00) | LMNAAPPGBA1MGAMFUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197625-A1 | SYNTHETIC LIPOPHILIC INOSITOL GLYCANS FOR TREATMENT OF CANCER AND GLUCOSE-METABOLISM DISORDERS | TRUSTEES OF TUFTS COLLEGE | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197625-A1 | SYNTHETIC LIPOPHILIC INOSITOL GLYCANS FOR TREATMENT OF CANCER AND GLUCOSE-METABOLISM DISORDERS | UGCG, GPR119, GPI | LMNA 2388/4885APP 4026/4885GBA1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.